This clinical trial is focused on studying a type of prostate cancer known as Metastatic Castration-Resistant Prostate Cancer (mCRPC). This is a form of prostate cancer that has spread to other parts of the body and continues to grow even when the amount of testosterone in the body is reduced to very low levels. The study is investigating the effectiveness of a new treatment combination that includes the drug Fuzuloparib, along with Abiraterone Acetate and Prednisone (referred to as AA-P). Fuzuloparib is being tested to see if it can improve outcomes when added to the standard treatment of AA-P.

The purpose of the study is to determine if the combination of Fuzuloparib with AA-P is more effective than a placebo combined with AA-P as a first-line treatment for patients with mCRPC. Participants in the study will be randomly assigned to receive either the Fuzuloparib combination or the placebo combination. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medications orally, as they are in the form of tablets or capsules. The study will monitor the progression of the cancer and assess the overall health and survival of the participants. The trial aims to provide valuable information on whether adding Fuzuloparib to the existing treatment can offer better outcomes for patients with this challenging form of prostate cancer.